-
-
Approved IBS drug Bentyl may help overcome chemo-resistant prostate cancer
-
Ionis’ HAE drug bests placebo in phase 3, setting up run to FDA approval
FDA clears vibrating belt to boost brittle bones in women facing osteoporosis
Roche’s Genentech returns Alzheimer’s assets to AC Immune, cutting 18-year tie to the biotech
Sagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries
In The News
- Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
- UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
- Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team
Biotechnology Daily
more-
Approved IBS drug Bentyl may help overcome chemo-resistant prostate cancer
A drug used to treat irritable bowel syndrome (IBS) appears to be effective against prostate…
Ionis’ HAE drug bests placebo in phase 3, setting up run to FDA approval
FDA clears vibrating belt to boost brittle bones in women facing osteoporosis
Roche’s Genentech returns Alzheimer’s assets to AC Immune, cutting 18-year tie to the biotech
FDA lifts remaining hold on Pharvaris’ HAE drug, clearing path to phase 3
Market Watch
more-
Weekly Market Review – April 27, 2024
Stock Markets All major indexes are up this week. The Dow Jones Industrial Index (DJIA)…
US Growth Slowed Sharply Last Quarter to 1.6% Pace, Reflecting an Economy Pressured by High Rates
GDP Grew Only 1.6% in Q1 in First Sign of Slowing Growth as Businesses Trimmed Inventories, Imports Surged
Southwest Airlines Flight Attendants Ratify a Contract That Will Raise Pay About 33% Over 4 Years
Wall Street Falls on Double Dose of Disappointing Economic Data, as Meta Sinks
Bio Business News
moreSagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries
Sagimet Biosciences has eased the pain of investors who backed…
Arrivent anticipates $135M IPO as biotechs continue to eye public market
As one of the first in a new year wave…
Itch treater Cara cuts 50% of team to extend cash runway into 2026
Despite having an FDA-approved injectable product, pruritus-focused drug developer Cara…
World News
moreStocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
- Weekly Market Review – April 27, 2024
- Approved IBS drug Bentyl may help overcome chemo-resistant prostate cancer
- Ionis’ HAE drug bests placebo in phase 3, setting up run to FDA approval
- FDA clears vibrating belt to boost brittle bones in women facing osteoporosis
- Roche’s Genentech returns Alzheimer’s assets to AC Immune, cutting 18-year tie to the biotech
- Sagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries
- Arrivent anticipates $135M IPO as biotechs continue to eye public market
- Itch treater Cara cuts 50% of team to extend cash runway into 2026
- Natera offers $52.5M for Invitae’s reproductive health screening tests after patent spat
- US Growth Slowed Sharply Last Quarter to 1.6% Pace, Reflecting an Economy Pressured by High Rates